Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):858–862. doi: 10.1038/bjc.1994.166

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

J Ma 1, J Verweij 1, H J Kolker 1, H E van Ingen 1, G Stoter 1, J H Schellens 1
PMCID: PMC1968910  PMID: 8180014

Abstract

The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROV1 human ovarian cancer cell line. Disappearance of pharmacologically active unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP between the three dose-input functions (AUC i.v. bolus, 6.34 +/- 0.36; 3 h infusion, 6.35 +/- 0.59; and 20 h infusion, 6.76 +/- 0.40 micrograms h ml-1). Also, the differences between the area under the CDDP-DNA adduct-time curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These relationships were not significantly different between the three dose-input functions. Variation in the rate of input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell survival.

Full text

PDF
858

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bajorin D. F., Bosl G. J., Alcock N. W., Niedzwiecki D., Gallina E., Shurgot B. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Cancer Res. 1986 Nov;46(11):5969–5972. [PubMed] [Google Scholar]
  2. Bénard J., Da Silva J., De Blois M. C., Boyer P., Duvillard P., Chiric E., Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res. 1985 Oct;45(10):4970–4979. [PubMed] [Google Scholar]
  3. Fichtinger-Schepman A. M., van Oosterom A. T., Lohman P. H., Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res. 1987 Jun 1;47(11):3000–3004. [PubMed] [Google Scholar]
  4. Forastiere A. A., Takasugi B. J., Baker S. R., Wolf G. T., Kudla-Hatch V. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol. 1987;19(2):155–158. doi: 10.1007/BF00254569. [DOI] [PubMed] [Google Scholar]
  5. Holding J. D., Lindup W. E., van Laer C., Vreeburg G. C., Schilling V., Wilson J. A., Stell P. M. Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. Br J Clin Pharmacol. 1992 Jan;33(1):75–81. doi: 10.1111/j.1365-2125.1992.tb04003.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jacobs C., Bertino J. R., Goffinet D. R., Fee W. E., Goode R. L. 24-hour infusion of cis-platinum in head and neck cancers. Cancer. 1978 Nov;42(5):2135–2140. doi: 10.1002/1097-0142(197811)42:5<2135::aid-cncr2820420508>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  7. Kovacs C. J., Braunschweiger P. G., Schenken L. L., Burholt D. R. Proliferative defects in renal and intestinal epithelium after cis-dichlorodiammine platinum (II). Br J Cancer. 1982 Feb;45(2):286–294. doi: 10.1038/bjc.1982.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  9. Meijer S., Mulder N. H., Sleijfer D. T., Donker A. J., Sluiter W. J., de Jong P. E., Schraffordt Koops H., van der Hem G. K. Influence of combination chemotherapy with cis-diamminedichloroplatinum on renal function: long-term effects. Oncology. 1983;40(3):170–173. doi: 10.1159/000225718. [DOI] [PubMed] [Google Scholar]
  10. Plooy A. C., van Dijk M., Lohman P. H. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res. 1984 May;44(5):2043–2051. [PubMed] [Google Scholar]
  11. Reed E., Ostchega Y., Steinberg S. M., Yuspa S. H., Young R. C., Ozols R. F., Poirier M. C. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res. 1990 Apr 15;50(8):2256–2260. [PubMed] [Google Scholar]
  12. Reed E., Ozols R. F., Tarone R., Yuspa S. H., Poirier M. C. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis. 1988 Oct;9(10):1909–1911. doi: 10.1093/carcin/9.10.1909. [DOI] [PubMed] [Google Scholar]
  13. Salem P., Khalyl M., Jabboury K., Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer. 1984 Feb 15;53(4):837–840. doi: 10.1002/1097-0142(19840215)53:4<837::aid-cncr2820530403>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  14. Teyssier J. R., Bénard J., Ferre D., Da Silva J., Renaud L. Drug-related chromosomal changes in chemoresistant human ovarian carcinoma cells. Cancer Genet Cytogenet. 1989 May;39(1):35–43. doi: 10.1016/0165-4608(89)90227-6. [DOI] [PubMed] [Google Scholar]
  15. Troger V., Fischel J. L., Formento P., Gioanni J., Milano G. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur J Cancer. 1992;28(1):82–86. doi: 10.1016/0959-8049(92)90391-e. [DOI] [PubMed] [Google Scholar]
  16. Vermorken J. B., Kapteijn T. S., Hart A. A., Pinedo H. M. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol. 1983 Jan;19(1):53–58. doi: 10.1016/0277-5379(83)90398-x. [DOI] [PubMed] [Google Scholar]
  17. Vermorken J. B., van der Vijgh W. J., Klein I., Gall H. E., Pinedo H. M. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069–1074. doi: 10.1016/0277-5379(82)90085-2. [DOI] [PubMed] [Google Scholar]
  18. Vermorken J. B., van der Vijgh W. J., Klein I., Gall H. E., van Groeningen C. J., Hart G. A., Pinedo H. M. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther. 1986 Feb;39(2):136–144. doi: 10.1038/clpt.1986.24. [DOI] [PubMed] [Google Scholar]
  19. Vogelzang N. J. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984 Nov;2(11):1289–1304. doi: 10.1200/JCO.1984.2.11.1289. [DOI] [PubMed] [Google Scholar]
  20. Yotsuyanagi T., Ohta N., Futo T., Ito S., Chen D. N., Ikeda K. Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding. Chem Pharm Bull (Tokyo) 1991 Nov;39(11):3003–3006. doi: 10.1248/cpb.39.3003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES